Image

E-intervention on Subclinical Fear of Cancer Recurrence

E-intervention on Subclinical Fear of Cancer Recurrence

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The present study aims to adapt a metacognition-based ConquerFear-HK to an internet-based self-management intervention, namely eConquerFear-HK and evaluate in a randomised controlled trial, its feasibility, utility, and potential effectiveness on fear of cancer recurrence reduction among local Chinese cancer survivors with subclinical fear of cancer recurrence.

Description

A pilot randomised controlled feasibility trial will used to test the feasibility, utility, and potential effectiveness of an internet-based self-management intervention for fear of cancer recurrence among local Chinese cancer survivors with subclinical fear of cancer recurrence.

The following hypotheses will be tested:

  1. There will be a greater FCR improvement in cancer survivors receiving eConquerFear-HK intervention vs those in the active control group.
  2. There will be a greater MCQ reduction in cancer survivors receiving eConquerFear-HK intervention vs those in the active control group.
  3. There will be greater improvements in secondary outcomes (psychological distress and quality of life) in cancer survivors receiving eConquerFear-HK intervention vs those in the active control group.
  4. Cancer survivors receiving eConquerFear-HK intervention will perceive the intervention useful for managing their FCR and be satisfied with the intervention.
  5. Cancer survivors receiving eConquerFear-HK intervention will show high completion rates.

Eligibility

Inclusion Criteria:

  • Cantonese- or Mandarin-speaking Chinese cancer survivors
  • recently diagnosed with potentially curable (stage 0 to III) colorectal or breast cancer
  • had recently completed surgery as primary treatment
  • have completed hospital-based adjuvant treatments (including radiotherapy and chemotherapy) within the past six months
  • scored 13 to 21 on the fear of cancer recurrence-short form will be recruited.

Exclusion Criteria:

  • non-Chinese ethnicity
  • metastatic cancer
  • with current diagnosis of depression or psychosis or are currently receiving psychological treatments
  • language or intellectual difficulties that prevent them from understanding the intervention content
  • having limited or no Internet access.

Study details
    Cancer
    Psychooncology
    Fear of Cancer Recurrence

NCT06207006

The University of Hong Kong

17 May 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.